Astria Therapeutics (ATXS) Price & Analysis

Compare

1,160 Followers

ATXS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.56 - $12.52

Previous CloseN/A

Volume35.54K

Average Volume (3M)399.45K

Market Cap

$421.57M

Enterprise Value$151.82M

Total Cash (Recent Filing)$259.18M

Total Debt (Recent Filing)$4.77M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Nov 12, 2025

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding56,434,895

10 Day Avg. Volume370,432

30 Day Avg. Volume399,452

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.36

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.16

Forecast

1Y Price Target

$29.89

Price Target Upside255.83% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart is a further sign of development progress and enthusiasm for the treatment in the HAE space.

Financial PositionAstria has updated its cash runway guidance to extend into 2028, indicating a strengthened financial position due to the partnership with Kaken Pharmaceutical.

Market ExpansionAstria's partnership with Kaken Pharmaceutical represents a strategic opportunity to broaden navenibart’s market reach and validate its potential as a first-in-class HAE therapy option.

Bears Say

Competitive LandscapeNavenibart is positioned as a potential first-choice preventative treatment in HAE, with an efficacy profile that could exceed competitors.

Treatment EfficacyThe wider therapeutic window could drive lasting efficacy for people living with AD, particularly the significant portion of patients who do not respond to current approved biologics.

Astria Therapeutics News

Astria Therapeutics initiates ORBIT-EXPANSE trial

Astria Therapeutics (ATXS) announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart in people living...

2d ago

ATXS

Astria Therapeutics begins enrollment in EU for ALPHA-ORBIT trial

Astria Therapeutics (ATXS) announced that it has begun opening clinical trial sites in the European Union and may...

8d ago

ATXS

Astria Therapeutics price target raised to $26 from $25 at Evercore ISI

Evercore ISI raised the firm’s price target on Astria Therapeutics (ATXS) to $26 from $25 and keeps an...

9d ago

ATXS

Astria Therapeutics price target raised to $20 from $16 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Astria Therapeutics (ATXS) to $20 from $16 and keeps a...

23d ago

ATXS

Astria delivers on all objectives in STAR-0310 trial, says Cantor Fitzgerald

Astria delivered on all of its objectives for STAR-0310, an OX40 antibody, in a Phase 1 trial, Cantor...

23d ago

ATXS

Astria Therapeutics announces initial results from STAR-0310 trial

Astria Therapeutics (ATXS) announced initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal...

23d ago

ATXS

Promising Developments in Astria Therapeutics’ Clinical Program Justify Buy Rating

Astria Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

2d ago

ATXS

Buy Rating for Astria Therapeutics: Promising Clinical Data and Market Advantages of STAR-0310

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Astria Therapeutics, retaining the price target of...

22d ago

ATXS

Promising Potential of Astria Therapeutics’ STAR-0310 in Atopic Dermatitis: Analyst Recommends Buy

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on ATXS stock, giving a Buy rating today....

23d ago

ATXS

Promising Developments and Financial Stability Drive Buy Rating for Astria Therapeutics

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ATXS stock, giving a Buy rating on...

2M ago

ATXS

Astria Therapeutics price target raised to $26 from $25 at Citizens JMP

Citizens JMP raised the firm’s price target on Astria Therapeutics (ATXS) to $26 from $25 and keeps an...

2M ago

ATXS

Strong Financial Position and Strategic Partnerships Drive Buy Rating for Astria Therapeutics

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Astria Therapeutics and keeping the price target...

2M ago

ATXS

Astria Therapeutics Reports Increased Losses Amid R&D Expansion

Astria Therapeutics, Inc. ( ($ATXS) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ATXS

Astria Therapeutics reports Q2 EPS (57c), consensus (58c)

“Delivering on navenibart’s best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial...

2M ago

ATXS

ATXS FAQ

What was Astria Therapeutics’s price range in the past 12 months?

Astria Therapeutics lowest stock price was $3.56 and its highest was $12.52 in the past 12 months.

What is Astria Therapeutics’s market cap?

Astria Therapeutics’s market cap is $421.57M.

When is Astria Therapeutics’s upcoming earnings report date?

Astria Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 33 days.

How were Astria Therapeutics’s earnings last quarter?

Astria Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.588 by $0.018.

Is Astria Therapeutics overvalued?

According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Astria Therapeutics pay dividends?

Astria Therapeutics does not currently pay dividends.

What is Astria Therapeutics’s EPS estimate?

Astria Therapeutics’s EPS estimate is -0.42.

How many shares outstanding does Astria Therapeutics have?

Astria Therapeutics has 56,434,895 shares outstanding.

What happened to Astria Therapeutics’s price movement after its last earnings report?

Astria Therapeutics reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.588. Following the earnings report the stock price went up 3.308%.

Which hedge fund is a major shareholder of Astria Therapeutics?

Currently, no hedge funds are holding shares in ATXS

Astria Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-38.49%

Trailing 12-Months

Asset Growth

-23.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Astria Therapeutics

Astria Therapeutics (ATXS) is a biopharmaceutical company focused on discovering and developing therapies for rare and niche diseases. The company's core mission is to create transformative treatments that improve the lives of patients with unmet medical needs. Astria Therapeutics leverages deep scientific expertise to advance its pipeline of innovative drug candidates targeting specific disease mechanisms.

Astria Therapeutics (ATXS) Earnings & Revenues

Historic Earnings Reports

ATXS Stock 12 Month Forecast

Average Price Target

$29.89

▲(255.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","50":"$50","14.75":"$14.75","26.5":"$26.5","38.25":"$38.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.75,26.5,38.25,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,10.72923076923077,13.918461538461539,17.107692307692307,20.296923076923076,23.486153846153844,26.675384615384615,29.864615384615384,33.05384615384615,36.24307692307692,39.43230769230769,42.62153846153846,45.81076923076923,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,9.259230769230768,10.978461538461538,12.697692307692307,14.416923076923077,16.136153846153846,17.855384615384615,19.574615384615385,21.293846153846154,23.013076923076923,24.732307692307693,26.451538461538462,28.17076923076923,{"y":29.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,8.49846153846154,9.456923076923077,10.415384615384616,11.373846153846154,12.332307692307692,13.290769230769232,14.24923076923077,15.207692307692309,16.166153846153847,17.124615384615385,18.083076923076923,19.04153846153846,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >